Mydecine Innovations strikes five-year research agreement with Johns Hopkins University to study psychedelic therapies
Johns Hopkins University has been at the forefront of psychedelic research since the early 2000’s. Now, its researchers are partnering with Mydecine Innovations (MYCO) to end one of the most difficult addictions to treat.
The Denver-based company just signed into a 5-year research agreement with Johns Hopkins to study psychedelic therapies. Initial research will focus on smoking cession, expanding on previous findings that 80% of smokers were able to quit after one dose of psilocybin.
Mydecine also announced that it has added 4 news lead drug candidates to its portfolio.